Cited 0 times in 
Cited 0 times in 
Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: Updated HER-RAM study with biomarker analysis
https://orcid.org/0000-0003-2292-5584
https://orcid.org/0000-0002-0625-9828
https://orcid.org/0000-0002-2512-4531
https://orcid.org/0000-0001-5151-5096
https://orcid.org/0000-0001-8281-3387
https://orcid.org/0000-0002-0920-9471
https://orcid.org/0000-0003-0952-3679Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.